US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a negative coverage decision for Eli Lilly’s Kisunla came in October 2024. Following a request ...
Pharmaceutical Technology on MSN8d
UK’s pricing watchdog rejects Alzheimer treatments for the second timeThe UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...
lecanemab (Leqembi) and donanemab (Kisunla). Both FDA-approved medications are designed to remove amyloid beta plaques from the brains of people with early-stage Alzheimer's disease, potentially ...
Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...
"I think it helped," says her husband, Ken Bell. "But I'm not sure." That sort of uncertainty is common when it comes to ...
Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback